BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical firm dedicated to bringing transformative bifunctional therapies to sufferers with stable tumors, right this moment introduced the pricing of its preliminary public providing of 17,500,000 shares of its frequent inventory at a public providing worth of $18.00 per share. Bicara Therapeutics’ shares are anticipated to start buying and selling on the Nasdaq International Market on September 13, 2024 beneath the ticker image BCAX. The providing is anticipated to shut on September 16, 2024, topic to the satisfaction of customary closing situations. As well as, Bicara Therapeutics has granted the underwriters a 30-day choice to buy as much as a further 2,625,000 shares of its frequent inventory on the public providing worth, much less underwriting reductions and commissions. The entire shares of frequent inventory are being provided by Bicara Therapeutics.
Morgan Stanley , TD Cowen, Cantor and Stifel are appearing as joint bookrunners for the providing.
The gross proceeds to Bicara Therapeutics from the preliminary public providing, earlier than deducting underwriting reductions and commissions and different providing bills payable by Bicara Therapeutics, are anticipated to be roughly $315.00 million, excluding any train of the underwriters’ choice to buy extra shares of frequent inventory.
A registration assertion referring to the shares offered within the preliminary public providing has been filed with the Securities and Alternate Fee and was declared efficient on September 12, 2024. The providing is being made solely via a prospectus. A replica of the ultimate prospectus, when obtainable, could also be obtained from: Morgan Stanley & Co (NYSE:). LLC, Consideration: Prospectus Division, 180 Varick Avenue, 2nd Ground, New York, NY 10014, by phone at (866) 718-1649, or by e mail at prospectus@morganstanley.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by phone at (855) 495-9846, or by e mail at TD.ECM_Prospectus@tdsecurities.com; Cantor Fitzgerald & Co., Consideration: Capital Markets, 110 East 59th  Avenue, sixth  Ground, New York, New York 10022 or by e mail at prospectus@cantor.com; or Stifel, Nicolaus & Firm, Integrated, Consideration: Prospectus Division, One Montgomery Avenue, Suite 3700, San Francisco, CA 94104 by phone at (415) 364-2720 or by e mail at  syndprospectus@stifel.com.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction during which such provide, solicitation or sale could be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical firm dedicated to bringing transformative bifunctional therapies to sufferers with stable tumors. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that mixes two clinically validated targets, an epidermal development issue receptor (EGFR) directed monoclonal antibody with a site that binds to human reworking development issue beta (TGF-β). By way of this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor exercise by concurrently blocking each most cancers cell-intrinsic EGFR survival and proliferation, in addition to the immunosuppressive  TGF-β  signaling throughout the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, the place there stays a big unmet want.
Cautionary Observe Relating to Ahead-Wanting Statements
This press launch consists of sure disclosures that include forward-looking statements, together with, with out limitation, statements relating to Bicara Therapeutics’ expectations relating to the graduation of buying and selling of its shares on the Nasdaq International Market, the completion and timing of the closing of the providing and the anticipated gross proceeds from the providing. Ahead-looking statements are based mostly on Bicara Therapeutics’ present expectations and are topic to inherent uncertainties, dangers and assumptions which are troublesome to foretell. Components that would trigger precise outcomes to vary embody, however aren’t restricted to, dangers and uncertainties associated to the satisfaction of customary closing situations and the completion of the providing, and the dangers inherent in biopharmaceutical product improvement and medical trials. These and different dangers and uncertainties are described extra absolutely within the part titled Threat Components part of the registration assertion filed with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date, and Bicara Therapeutics undertakes no responsibility to replace such info besides as required beneath relevant legislation. Readers shouldn’t depend upon the data on this web page as present or correct after its publication date.
Contacts
Buyers
Rachel Frank
ir@bicara.com
Media
Dan Budwick
1AB
dan@1abmedia.com
Supply: Bicara Therapeutics Inc.
